{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"description":"A SAE was defined as any adverse event that fulfilled at least one of the following criteria: •Was fatal (results in death) •Was life-threatening •Required in-patient hospitalization or prolongation of existing hospitalization •Resulted in persistent or significant disability/incapacity •Was a congenital anomaly/birth defect •Was medically significant or required intervention to prevent one or other of the outcomes listed above.","groups":[{"description":"Participants with GPA (Wegener's granulomatosis) or MPA who received rituximab as per investigator's discretion were followed for a maximum of 4.32 years.","id":"OG000","title":"Rituximab"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who received any active dose of rituximab.","reportingStatus":"POSTED","timeFrame":"From the start of an infusion up to 24 hours following infusion completion (Up to 4.32 years)","title":"Percentage of Participants With Any Serious Adverse Events During or Within 24 Hours After Any Rituximab Infusion","type":"SECONDARY","unitOfMeasure":"percentage of participants"}